Switch theme
Sign up to access all valuation multiples
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
2015
56
LTM Revenue $21.6M
LTM EBITDA -$99.4M
$70.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PureTech Health has a last 12-month revenue (LTM) of $21.6M and a last 12-month EBITDA of -$99.4M.
In the most recent fiscal year, PureTech Health achieved revenue of $5.9M and an EBITDA of $51.3M.
PureTech Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PureTech Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.6M | XXX | $5.9M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$99.4M | XXX | $51.3M | XXX | XXX | XXX |
| EBITDA Margin | -459% | XXX | 866% | XXX | XXX | XXX |
| EBIT | -$97.1M | XXX | -$187M | XXX | XXX | XXX |
| EBIT Margin | -449% | XXX | -3154% | XXX | XXX | XXX |
| Net Profit | -$27.5M | XXX | $73.5M | XXX | XXX | XXX |
| Net Margin | -127% | XXX | 1240% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, PureTech Health's stock price is GBP 1 (or $2).
PureTech Health has current market cap of GBP 303M (or $416M), and EV of GBP 51.5M (or $70.7M).
See PureTech Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70.7M | $416M | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, PureTech Health has market cap of $416M and EV of $70.7M.
PureTech Health's trades at 11.9x EV/Revenue multiple, and 1.4x EV/EBITDA.
Equity research analysts estimate PureTech Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PureTech Health has a P/E ratio of -11.0x.
See valuation multiples for PureTech Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $416M | XXX | $416M | XXX | XXX | XXX |
| EV (current) | $70.7M | XXX | $70.7M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBIT | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.0x | XXX | 5.7x | XXX | XXX | XXX |
| EV/FCF | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPureTech Health's last 12 month revenue growth is 82%
PureTech Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.4M for the same period.
PureTech Health's rule of 40 is -2275% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PureTech Health's rule of X is -253% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PureTech Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 82% | XXX | 202% | XXX | XXX | XXX |
| EBITDA Margin | -459% | XXX | 866% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2275% | XXX | 949% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -253% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1258% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3254% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PureTech Health acquired XXX companies to date.
Last acquisition by PureTech Health was XXXXXXXX, XXXXX XXXXX XXXXXX . PureTech Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PureTech Health founded? | PureTech Health was founded in 2015. |
| Where is PureTech Health headquartered? | PureTech Health is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does PureTech Health have? | As of today, PureTech Health has 56 employees. |
| Who is the CEO of PureTech Health? | PureTech Health's CEO is Dr. Bharatt M. Chowrira. |
| Is PureTech Health publicy listed? | Yes, PureTech Health is a public company listed on LON. |
| What is the stock symbol of PureTech Health? | PureTech Health trades under PRTC ticker. |
| When did PureTech Health go public? | PureTech Health went public in 2015. |
| Who are competitors of PureTech Health? | Similar companies to PureTech Health include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PureTech Health? | PureTech Health's current market cap is $416M |
| What is the current revenue of PureTech Health? | PureTech Health's last 12 months revenue is $21.6M. |
| What is the current revenue growth of PureTech Health? | PureTech Health revenue growth (NTM/LTM) is 82%. |
| What is the current EV/Revenue multiple of PureTech Health? | Current revenue multiple of PureTech Health is 2.4x. |
| Is PureTech Health profitable? | Yes, PureTech Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PureTech Health? | PureTech Health's last 12 months EBITDA is -$99.4M. |
| What is PureTech Health's EBITDA margin? | PureTech Health's last 12 months EBITDA margin is -459%. |
| What is the current EV/EBITDA multiple of PureTech Health? | Current EBITDA multiple of PureTech Health is -0.5x. |
| What is the current FCF of PureTech Health? | PureTech Health's last 12 months FCF is -$103M. |
| What is PureTech Health's FCF margin? | PureTech Health's last 12 months FCF margin is -478%. |
| What is the current EV/FCF multiple of PureTech Health? | Current FCF multiple of PureTech Health is -0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
